Schizophrenia Research
Volume 47, Issue 1 , Pages 37-47 , 15 January 2001

Elevated dopamine receptor-coupled Gs protein measures in mononuclear leukocytes of patients with schizophrenia

  • Sofia Avissar

      Affiliations

    • Department of Clinical Pharmacology, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel
    • Corresponding Author InformationCorresponding author. Tel.: +972-7-6467478; fax: +972-7-6460710
    • ,
  • Liza Barki-Harrington

      Affiliations

    • Department of Clinical Pharmacology, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel
    • ,
  • Yakov Nechamkin

      Affiliations

    • Department of Psychiatry, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel
    • ,
  • Gregori Roitman

      Affiliations

    • Department of Psychiatry, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel
    • ,
  • Gabriel Schreiber

      Affiliations

    • Department of Psychiatry, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel

Received 24 September 1999 ,Accepted 23 February 2000.

References 

  1. Agid Y, Cervera P, Hirsch E. Biochemistry of Parkinson's disease 28 years later: a critical review. Move. Dis. 1989;4:S126–S144
  2. Avissar S, Schreiber G. Muscarinic receptor subclassification and G proteins: significance for lithium action in affective disorders and for the treatment of the extrapyramidal side effects of neuroleptics (Bennett Award Paper). Biol. Psychiatry. 1989;26:113–130
  3. Avissar S, Schreiber G. The involvement of G proteins in the pathogenesis and treatment of affective disorders. Biol. Psychiatry. 1992;31:435–459
  4. Avissar S, Schreiber G. Interaction of antibipolar and antidepressant treatments with receptor-coupled G proteins. Pharmacopsychiatry. 1992;25:44–50
  5. Avissar S, Schreiber G. Measurement of early events in signal transduction beyond receptors involving G proteins function in mononuclear leukocytes. J. Neuroimmunol. 1996;70:81–86
  6. Avissar S, Schreiber G, Danon A, Belmaker RH. Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex. Nature. 1988;331:440–442
  7. Avissar S, Schreiber G, Aulakh CS, Murphy DL. Carbamazepine and electroconvulsive shock attenuate beta-adrenoceptor and muscarinic cholinoceptor coupling to G proteins in rat cortex. Eur. J. Pharmacol. 1990;100:99–103
  8. Avissar S, Murphy DL, Schreiber G. Magnesium reverses lithium inhibition of beta adrenergic and muscarinic receptor coupling to G proteins. Biochem. Pharmacol. 1991;41:171–175
  9. Avissar S, Barki-Harrington L, Nechamkin Y, Roitman G, Schreiber G. Reduced β-adrenergic receptor-coupled Gs protein function and Gsα immunoreactivity in mononuclear leukocytes of patients with depression. Biol. Psychiatry. 1996;39:755–760
  10. Avissar S, Nechamkin Y, Barki-Harrington L, Roitman G, Schreiber G. Differential G protein measures in mononuclear leukocytes of patients with bipolar mood disorder are state dependent. J. Affect. Disord. 1997;43:85–93
  11. Avissar S, Nechamkin Y, Roitman G, Schreiber G. Reduced G protein functions and immunoreactive levels in mononuclear leukocytes of patients with depression. Am. J. Psychiatry. 1997;154:211–217
  12. Avissar S, Barki-Harrington L, Herishanu Y, Schreiber G. Reduced Gs protein function and Gsα immunoreactive levels in leukocytes of patients with Parkinson's disease. Move. Dis. 1997;12:167–174
  13. Avissar S, Nechamkin Y, Roitman G, Schreiber G. Dynamics of ECT normalization of low G protein function and immunoreactivity in mononuclear leukocytes of patients with major depression. Am. J. Psychiatry. 1998;155:666–671
  14. Avissar S, Schreiber G, Nechamkin Y, Neuhaus I, Lam GK, Schwartz P, et al. The effects of seasons and light therapy on G proteins levels in mononuclear leukocytes of patients with seasonal affective disorder. Arch. Gen. Psychiatry. 1999;56:178–183
  15. Bargatze RF, Butcher EC. Rapid G protein-regulated activation event involved in lymphocyte binding to high endothelial venules. J. Exp. Med. 1993;78:367–372
  16. Barki-Harrington L, Nechamkin Y, Schreiber G, Avissar S. Functional and quantitative measures of receptor coupled G proteins in human mononuclear leukocytes: no change with age. Exp. Gerontol. 1996;31:351–363
  17. Bauer PH, Muller S, Puzicha M. Phosducin is a protein kinase A-regulated G-protein regulator. Nature. 1992;358:73–76
  18. Benovic JL, Bouvier M, Caron MG, Lefkowitz RJ. Regulation of adenylyl cyclase-coupled β-adrenergic receptors. Ann. Rev. Cell Biol. 1988;4:405–428
  19. Besedovsky HO, Del Rey A, Sorkin E, Da Prada M, Keller HH. Immunoregulation mediated by the sympathetic nervous system. Cell Immunol. 1979;48:346–355
  20. Cassel D, Selinger Z. Mechanism of adenylate cyclase activation through the β-adrenergic receptor: catecholamine-induced displacement of bound GDP by GTP. Proc. Nat. Acad. Sci. USA. 1978;75:4155–4159
  21. Evans SW, Beckner SK, Farrar WL. Stimulation of specific GTP binding and hydrolysis activities in lymphocyte membranes by IL-2. Nature. 1987;325:166–168
  22. Fergusson KM, Higashijima T, Smigel MD, Gilman AG. The influence of bound GDP on the kinetics of guanine nucleotide binding to G proteins. J. Biol. Chem. 1986;261:7393–7399
  23. Friedman E, Wang HY. Receptor-mediated activation of G proteins is increased in post-mortem brains of bipolar affective disorder subjects. J. Neurochem. 1996;67:1145–1152
  24. Friedman E, Wang HY. Effects of lithium on receptor-mediated activation of G proteins in rat brain cortical membranes. Neuropharmacol. 1999;38:403–414
  25. Gilman AG. G proteins — transducers of receptor-generated signals. Ann. Rev. Biochem. 1987;56:615–649
  26. Hadden JW, Hadden EM, Middeleton E. Lymphocyte blast transformation — demonstration of adrenergic receptor in human peripheral lymphocytes. Cell Immunol. 1979;1:583–595
  27. Hepler JR, Gilman AG. G proteins. Trends Biochem. Sci. 1992;17:383–387
  28. Johnson FN(Coordinator). Mechanisms of lithium action. Rev. Contemp. Pharmacoth. 1993;4:287–318
  29. Jope RS, Song L, Grimes CA, Pacheco MA, Dilley GE, Li X, et al. Selective increases in phosphoinositide signaling activity and G protein levels in post-mortem brain from subjects with schizophrenia or alcohol dependence. J. Neurochem. 1998;70:763–771
  30. Kahn RS, Davis KL. New developments in dopamine and schizophrenia. In:  Bloom FE,  Kupfer DJ editor. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press; 1955;p. 1193–1203
  31. Karege F, Bovier P, Stepanian R, Gaillard JM. Change in platelet GTP-binding protein in drug-free depressed patients. Human Psychopharmacol. 1996;11:115–121
  32. Kopin IJ. Parkinson's disease: past, present and future. Neuropsychopharmacol. 1993;9:1–12
  33. Kurose H, Katada T, Haga T, Haga K, Ichiyama A, Ui M. Functional interaction of purified muscarinic receptors with purified inhibitory guanine nucleotide regulatory proteins reconstituted in phospholipid vesicles. J. Biol. Chem. 1986;261:6423–6428
  34. Lappin D, Whaley K. Adrenergic receptors of monocytes modulate complement component synthesis. Clin. Exp. Immunol. 1982;47:606–612
  35. Livnat S, Felten SY, Carlson SL, Bellinger DL, Felten DL. Involvement of peripheral and central catecholamine systems in neural immune interactions. J. Neuroimmunol. 1985;10:5–30
  36. McColl SR, Hachicha M, Levasseur S, Neote K, Schall TJ. Uncoupling of early signal transduction events from effector function in human peripheral blood neutrophils in response to recombinant macrophage inflammatory proteins-1 alpha and -1 beta. J. Immunol. 1993;150:4550–4560
  37. Memo M, Kleinman JE, Hanbauer I. Coupling of dopamine D1 recognition sites with adenylate cyclase in nuclei accumbens and caudatus of schizophrenics. Science. 1983;221:1304–1307
  38. Murayama T, Ui M. [3H]-GDP release from rat and hamster adipocyte membranes. J. Biol. Chem. 1984;259:761–769
  39. Nagai Y, Ueno S, Saeki Y, Soga F, Yanagihara T. Expression of the D3 dopamine receptor gene and a novel variant transcript generated by alternative splicing in human peripheral blood lymphocytes. Biochem. Biophys. Res. Commun. 1993;194:368–374
  40. Nishino N, Kitamura N, Hashimoto T, Kajimoto Y, Shirai Y, Murakami N, et al. Increase in [3H]cAMP binding sites and decrease in Gi alpha and Go alpha immunoreactivities in left temporal cortices from patients with schizophrenia. Brain Res. 1993;615:41–49
  41. Northup JK, Smigel MD, Gilman AG. The guanine nucleotide activating site of the regulatory component of adenylate cyclase. Identification by ligand binding. J. Biol. Chem. 1982;257:11416–11423
  42. Okada F, Crow TJ, Roberts GW. G-proteins (Gi, Go) in the basal ganglia of control and schizophrenic brain. J. Neural Transm. 1990;79:227–234
  43. Okada F, Crow TJ, Roberts GW. G-proteins (Gi, Go) in the medial temporal lobe in schizophrenia: preliminary report of a neurochemical correlate of structural change. J. Neural Transm. 1991;84:147–153
  44. Okada F, Tokumitsu Y, Takahashi N, Crow TJ, Roberts GW. Reduced concentrations of the alpha-subunit of GTP-binding protein Go in schizophrenic brain. J. Neural Transm. 1994;95:95–104
  45. Ricci A, Amenta F. Dopamine D5 receptors in human peripheral blood lymphocytes: a radioligand binding study. J. Neuroimmunol. 1994;53:1–7
  46. Rossi A, Tria MA, Baschieri S, Doria G, Frasca D. Cholinergic agonists selectively induce proliferative responses in the mature subpopulation of murine thymocytes. J. Neurosci. Res. 1989;24:369–373
  47. Roszman TL, Brooks WH. Neural modulation of immune function. J. Neuroimmunol. 1985;10:59–69
  48. Santambrogio L, Lipartiti M, Bruni A, Dal Toso R. Dopamine receptors on human T- and B-lymphocytes. J. Neuroimmunol. 1993;45:113–120
  49. Schreiber G, Avissar S, Aulakh CS, Murphy DL. Lithium-selective alteration of brain vs. cardiac Gs protein function. Neuropharmacol. 1990;29:1067–1071
  50. Schreiber G, Avissar S, Danon A, Belmaker RH. Hyperfunctional G proteins in mononuclear leukocytes of patients with mania. Biol. Psychiatry. 1991;29:273–280
  51. Seeman P. Dopamine receptors–clinical correlates. In:  Bloom FE,  Kupfer DJ editor. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press; 1995;p. 295–302
  52. Sokal RR, Rohlf FJ. In: Biometry. second ed.. San Francisco: Freeman; 1981;p. 433
  53. Sternweis PC, Robishaw JD. Isolation of two proteins with high affinity for guanine nucleotides from membranes of bovine brain. J. Biol. Chem. 1984;259:13806–13813
  54. Takahashi N, Nagai Y, Ueno S, Saeki Y, Yanagihara T. Human peripheral blood lymphocytes express D5 dopamine receptor gene and transcribe the two pseudogenes. FEBS Lett. 1992;314:23–25
  55. Torre D, Pugliese A, Tambini R, Speranza F, Zeroli C. Production and release of tumor necrosis factor alfa, interleukin-1B and interleukin-6 by human mononuclear leukocytes stimulated with pertussis toxin. Microbiol. 1993;16:309–314
  56. Yang CQ, Kitamura N, Nishino N, Shirakawa O, Nakai H. Isotype-specific G protein abnormalities in the left superior temporal cortex and limbic structures of patients with chronic schizophrenia. Biol. Psychiatry. 1998;43:12–19
  57. Young LT, Li PP, Kish SJ, Siu KP, Warsh JJ. Post-mortem cerebral cortex Gsα subunit levels are elevated in bipolar affective disorder. Brain Res. 1991;553:323–326
  58. Young LT, Li PP, Kish SJ, Siu KP, Kamble A, Hornykiewics O, et al. Cerebral cortex Gs protein levels and forskolin-stimulated cyclic AMP formation are increased in bipolar affective disorder. J. Neurochem. 1993;61:890–898
  59. Zaleman SJ, Neckers LM, Kaayalp O, Wyatt RJ. Muscarinic cholinergic binding sites on intact human lymphocytes. Life Sci. 1981;29:69–73

PII: S0920-9964(00)00038-4

Schizophrenia Research
Volume 47, Issue 1 , Pages 37-47 , 15 January 2001

Article Tools

* Image Usage & Resolution